[
    [
        {
            "time": "2018-01-02",
            "original_text": "ROSEN, A TOP RANKED LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG â€“ NVS",
            "features": {
                "keywords": [
                    "Rosen",
                    "securities claims",
                    "investigation",
                    "Novartis"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Tagrisso",
                    "approval",
                    "China",
                    "NSCLC"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Novartis signs $840M pact with IFM Due amid fallout from AveXis deal",
            "features": {
                "keywords": [
                    "Novartis",
                    "IFM",
                    "pact",
                    "AveXis",
                    "deal"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]